title: P2X receptor antagonists for pain management: examination of binding and physicochemical properties.
abstract: Enhanced sensitivity to noxious stimuli and the perception of non-noxious stimuli as painful are hallmark sensory perturbations associated with chronic pain. It is now appreciated that ATP, through its actions as an excitatory neurotransmitter, plays a prominent role in the initiation and maintenance of chronic pain states. Mechanistically, the ability of ATP to drive nociceptive sensitivity is mediated through direct interactions at neuronal P2X3 and P2X2/3 receptors. Extracellular ATP also activates P2X4, P2X7, and several P2Y receptors on glial cells within the spinal cord, which leads to a heightened state of neural-glial cell interaction in ongoing pain states. Following the molecular identification of the P2 receptor superfamilies, selective small molecule antagonists for several P2 receptor subtypes were identified, which have been useful for investigating the role of specific P2X receptors in preclinical chronic pain models. More recently, several P2X receptor antagonists have advanced into clinical trials for inflammation and pain. The development of orally bioavailable blockers for ion channels, including the P2X receptors, has been traditionally difficult due to the necessity of combining requirements for target potency and selectivity with suitable absorption distribution, metabolism, and elimination properties. Recent studies on the physicochemical properties of marketed orally bioavailable drugs, have identified several parameters that appear critical for increasing the probability of achieving suitable bioavailability, central nervous system exposure, and acceptable safety necessary for clinical efficacy. This review provides an overview of the antinociceptive pharmacology of P2X receptor antagonists and the chemical diversity and drug-like properties for emerging antagonists of P2X3, P2X2/3, P2X4, and P2X7 receptors.
authors.affiliation: Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, R4DL, AP9A-3, 100 Abbott Park Road, Abbott Park, IL, 60064-6125, USA, rebecca.gum@abbott.com.
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Gum
authors.forename: Brian
authors.initials: B
authors.lastname: Wakefield
authors.forename: Michael F
authors.initials: MF
authors.lastname: Jarvis
references.citation: Nature. 2003 Aug 21;424(6951):938-42
references.pmid: 12931188
references.citation: Curr Opin Chem Biol. 2008 Jun;12(3):318-23
references.pmid: 18435937
references.citation: Expert Opin Ther Targets. 2008 May;12(5):647-61
references.pmid: 18410246
references.citation: Expert Opin Ther Pat. 2006 Aug;16(8):1113-27
references.pmid: 20144056
references.citation: Physiol Rev. 2007 Apr;87(2):659-797
references.pmid: 17429044
references.citation: Bioorg Med Chem Lett. 2010 Jan 1;20(1):362-5
references.pmid: 19897364
references.citation: Cell Res. 2000 Jun;10(2):93-102
references.pmid: 10896171
references.citation: J Med Chem. 2002 Sep 12;45(19):4057-93
references.pmid: 12213051
references.citation: Purinergic Signal. 2007 Sep;3(4):311-6
references.pmid: 18404444
references.citation: Glia. 2008 Apr;56(5):579-85
references.pmid: 18240312
references.citation: Expert Opin Ther Pat. 2010 May;20(5):625-46
references.pmid: 20205618
references.citation: Bioorg Med Chem. 2009 Oct 1;17(19):6890-7
references.pmid: 19740668
references.citation: Trends Neurosci. 2010 Jan;33(1):48-57
references.pmid: 19914722
references.citation: Br J Pharmacol. 2010 Jul;160(6):1387-98
references.pmid: 20590629
references.citation: J Med Chem. 2007 Jul 26;50(15):3706-15
references.pmid: 17585854
references.citation: Neuropharmacology. 2009 Jan;56(1):208-15
references.pmid: 18657557
references.citation: Expert Opin Ther Targets. 2003 Aug;7(4):513-22
references.pmid: 12885270
references.citation: Pain. 2003 Aug;104(3):471-480
references.pmid: 12927619
references.citation: ChemMedChem. 2009 Apr;4(4):680-6
references.pmid: 19266525
references.citation: J Neurosci. 2009 Mar 18;29(11):3518-28
references.pmid: 19295157
references.citation: Bioorg Med Chem Lett. 2009 Mar 15;19(6):1628-31
references.pmid: 19231180
references.citation: Br J Pharmacol. 2001 Jan;132(1):259-69
references.pmid: 11156585
references.citation: J Med Chem. 2009 May 28;52(10):3123-41
references.pmid: 19191585
references.citation: Pain. 2008 Jul;137(1):81-95
references.pmid: 17900807
references.citation: J Immunol. 2006 Apr 1;176(7):3877-83
references.pmid: 16547218
references.citation: Neuropharmacology. 2007 Sep;53(4):496-504
references.pmid: 17675190
references.citation: Glia. 2008 Jan 1;56(1):50-8
references.pmid: 17918263
references.citation: Br J Pharmacol. 2007 Jul;151(5):571-9
references.pmid: 17471177
references.citation: Nat Rev Neurosci. 2007 Jan;8(1):71-80
references.pmid: 17180164
references.citation: J Med Chem. 2009 Oct 22;52(20):6233-43
references.pmid: 19764786
references.citation: Mol Pharmacol. 2000 Jul;58(1):82-8
references.pmid: 10860929
references.citation: Drug Discov Today. 2009 Nov;14(21-22):1011-20
references.pmid: 19729075
references.citation: Pflugers Arch. 2006 Aug;452(5):513-37
references.pmid: 16649055
references.citation: Structure. 2009 Feb 13;17(2):266-75
references.pmid: 19217397
references.citation: Cell. 2009 Oct 16;139(2):267-84
references.pmid: 19837031
references.citation: J Pharmacol Exp Ther. 2006 Dec;319(3):1376-85
references.pmid: 16982702
references.citation: J Neurosci. 2008 Nov 26;28(48):12938-45
references.pmid: 19036987
references.citation: J Neurosci. 2009 Jan 28;29(4):998-1005
references.pmid: 19176808
references.citation: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
references.pmid: 11259830
references.citation: Behav Brain Res. 2006 Feb 28;167(2):355-64
references.pmid: 16256210
references.citation: Br J Pharmacol. 2009 Aug;157(7):1203-14
references.pmid: 19558545
references.citation: Br J Pharmacol. 1997 May;121(1):105-17
references.pmid: 9146894
references.citation: Pain. 1977 Aug;3(4):367-377
references.pmid: 198725
references.citation: Nature. 2006 Aug 3;442(7102):527-32
references.pmid: 16885977
references.citation: Br J Pharmacol. 1998 Aug;124(7):1463-6
references.pmid: 9723959
references.citation: Neuroscience. 2007 Jun 8;146(4):1817-28
references.pmid: 17478048
references.citation: Physiol Rev. 2002 Oct;82(4):1013-67
references.pmid: 12270951
references.citation: Purinergic Signal. 2010 Jun;6(2):145-8
references.pmid: 20806006
references.citation: J Pharmacol Exp Ther. 2008 Feb;324(2):409-15
references.pmid: 18042830
references.citation: Nat Biotechnol. 2006 Jul;24(7):805-15
references.pmid: 16841068
references.citation: Nature. 2005 Dec 15;438(7070):1017-21
references.pmid: 16355225
references.citation: J Immunol. 2002 Jun 15;168(12):6436-45
references.pmid: 12055263
references.citation: Drug Discov Today. 2005 Apr 1;10(7):464-9
references.pmid: 15809192
references.citation: J Med Chem. 2006 Jun 15;49(12):3659-66
references.pmid: 16759108
references.citation: ACS Chem Neurosci. 2010 Jun 16;1(6):420-34
references.pmid: 22778836
references.citation: J Biol Chem. 1994 May 27;269(21):15195-203
references.pmid: 8195155
references.citation: J Neurosci. 2008 Oct 29;28(44):11263-8
references.pmid: 18971468
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17179-84
references.pmid: 12482951
references.citation: Pain. 2011 Aug;152(8):1766-1776
references.pmid: 21565445
references.citation: Bioorg Med Chem Lett. 2008 Sep 1;18(17):4872-5
references.pmid: 18691886
references.citation: Bioorg Med Chem Lett. 2010 Feb 1;20(3):1031-6
references.pmid: 20045645
references.citation: Bioorg Med Chem Lett. 2009 Oct 1;19(19):5560-4
references.pmid: 19720530
references.citation: Neuroscience. 2007 Jun 29;147(2):445-55
references.pmid: 17543465
references.citation: Brain. 2000 Jun;123 ( Pt 6):1238-46
references.pmid: 10825361
references.citation: Pain. 2011 Mar;152(3 Suppl):S2-S15
references.pmid: 20961685
references.citation: Bioorg Med Chem Lett. 2010 May 15;20(10):3107-11
references.pmid: 20392639
references.citation: Handb Exp Pharmacol. 2007;(177):309-28
references.pmid: 17087128
references.citation: Br J Pharmacol. 2003 Oct;140(3):507-19
references.pmid: 14522842
references.citation: J Med Chem. 1997 Apr 25;40(9):1347-65
references.pmid: 9135032
references.citation: J Med Chem. 2003 Mar 27;46(7):1250-6
references.pmid: 12646035
references.citation: ACS Chem Neurosci. 2010 Jun 16;1(6):435-49
references.pmid: 22778837
references.citation: Pain. 2005 Apr;114(3):386-396
references.pmid: 15777864
references.citation: Purinergic Signal. 2009 Jun;5(2):129-37
references.pmid: 19212823
references.citation: Pharmacol Ther. 2006 Jan;109(1-2):210-26
references.pmid: 16169595
references.citation: NeuroRx. 2005 Oct;2(4):541-53
references.pmid: 16489364
references.citation: Nat Rev Drug Discov. 2007 Nov;6(11):881-90
references.pmid: 17971784
references.citation: J Pharmacol Exp Ther. 2008 Dec;327(3):620-33
references.pmid: 18772321
references.citation: Br J Pharmacol. 2003 Dec;140(8):1381-8
references.pmid: 14623769
references.citation: Bioorg Med Chem Lett. 2009 Mar 15;19(6):1632-5
references.pmid: 19231178
references.citation: Immunity. 2001 Nov;15(5):825-35
references.pmid: 11728343
references.citation: Nature. 2009 Jul 30;460(7255):592-8
references.pmid: 19641588
references.citation: Behav Brain Res. 2009 Dec 1;204(1):77-81
references.pmid: 19464323
references.citation: Mol Pharmacol. 2011 Aug;80(2):247-57
references.pmid: 21536754